All Stories

  1. Identification of Datura innoxia as a potential source of antimycobacterial components

    Article • Frontiers in Microbiology, July 2025, Frontiers

    Dr Sabira Tahseen

  2. Investigation of bedaquiline heteroresistance among Mycobacterium tuberculosis isolates from Pakistan

    Article • Microbiology Spectrum, April 2025, ASM Journals

    Dr Sabira Tahseen

  3. Prospective Exploratory Evaluation of Cepheid Xpert Mycobacterium tuberculosis Host Response Cartridge: A Focus on Adolescents and Young Adults

    Article • Clinical Infectious Diseases, September 2024, Oxford University Press (OUP)

    Dr Sabira Tahseen

  4. Unveiling the complexity of rifampicin drug susceptibility testing in Mycobacterium tuberculosis: comparative analysis with next-generation sequencing

    Article • Journal of Medical Microbiology, September 2024, Society for General Microbiology

    Dr Sabira Tahseen

  5. Insights into tuberculosis burden in Karachi, Pakistan: A concurrent adult tuberculosis prevalence and child Mycobacterium tuberculosis infection survey

    Article • PLOS Global Public Health, August 2024, PLOS

    Dr Sabira Tahseen

  6. A composite reference standard is needed for bedaquiline antimicrobial susceptibility testing forMycobacterium tuberculosiscomplex

    Article • European Respiratory Journal, July 2024, European Respiratory Society (ERS)

    Paolo Miotto, Dr Sabira Tahseen

  7. TB drug susceptibility testing in high fluoroquinolone resistance settings

    Article • IJTLD OPEN, May 2024, International Union Against Tuberculosis and Lung Disease

    Dr Sabira Tahseen

  8. Estimation of country-specific tuberculosis resistance antibiograms using pathogen genomics and machine learning

    Article • BMJ Global Health, March 2024, BMJ

    Dr Sabira Tahseen

  9. Quantitative measurement of antibiotic resistance in Mycobacterium tuberculosis reveals genetic determinants of resistance and susceptibility in a target gene approach

    Article • Nature Communications, January 2024, Springer Science + Business Media

    Paolo Miotto, Dr Sabira Tahseen

  10. Phenotype versus genotype discordant rifampicin susceptibility testing in tuberculosis: implications for a diagnostic accuracy

    Article • Microbiology Spectrum, January 2024, ASM Journals

    Dr Sabira Tahseen

  11. Healthcare seeking pathways and diagnostic delays among extra-pulmonary tuberculosis patients: a study from Pakistan

    Article • September 2022, European Respiratory Society (ERS)

    Dr Sabira Tahseen

  12. A data compendium associating the genomes of 12,289 Mycobacterium tuberculosis isolates with quantitative resistance phenotypes to 13 antibiotics

    Article • PLoS Biology, August 2022, PLOS

    Jennifer Guthrie, Dr Sabira Tahseen

  13. The value of histological examination in the diagnosis of tuberculous lymphadenitis in the era of rapid molecular diagnosis

    Article • Scientific Reports, May 2022, Springer Science + Business Media

    Dr Sabira Tahseen

  14. Updating the approaches to define susceptibility and resistance to anti-tuberculosis agents: implications for diagnosis and treatment

    Article • European Respiratory Journal, April 2022, European Respiratory Society (ERS)

    Paolo Miotto, Dr. Jaime Robledo, Professor Miguel Viveiros, Dr Sabira Tahseen

  15. The 2021 WHO catalogue of Mycobacterium tuberculosis complex mutations associated with drug resistance: a genotypic analysis

    Article • The Lancet Microbe, April 2022, Elsevier

    Paolo Miotto, Dr. Jaime Robledo, Jennifer Guthrie, Dr Sabira Tahseen

  16. Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing ofM. tuberculosis

    Article • European Respiratory Journal, March 2022, European Respiratory Society (ERS)

    Philip Fowler, Jennifer Guthrie, Dr Sabira Tahseen

  17. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective In Vitro Surveillance Study of Bedaquiline and Other Second-Line Drug Susceptibility Testing in MDR-TB Is...

    Article • Journal of Clinical Microbiology, January 2022, ASM Journals

    Dr Sabira Tahseen

  18. In vivo Microevolution of Mycobacterium tuberculosis and transient emergence of atpE_Ala63Pro mutation during treatment in a pre-XDR TB patient

    Article • European Respiratory Journal, November 2021, European Respiratory Society (ERS)

    Dr Sabira Tahseen

  19. Predictors of slow clinical response and extended treatment in patients with extra-pulmonary tuberculosis in Pakistan, A hospital-based prospective study

    Article • PLOS One, November 2021, PLOS

    Dr Sabira Tahseen

  20. Profiling and identification of novel rpoB mutations in rifampicin-resistant Mycobacterium tuberculosis clinical isolates from Pakistan

    Article • Journal of Infection and Chemotherapy, November 2021, Elsevier

    Dr Sabira Tahseen

  21. Population structure, biogeography and transmissibility of Mycobacterium tuberculosis

    Article • Nature Communications, October 2021, Springer Science + Business Media

    Dr Sabira Tahseen

  22. Role of Epistasis in Amikacin, Kanamycin, Bedaquiline, and Clofazimine Resistance in Mycobacterium tuberculosis Complex

    Article • Antimicrobial Agents and Chemotherapy, October 2021, ASM Journals

    Paolo Miotto, Dr Sabira Tahseen

  23. Phenotypic vs. genotypic resistance to fluoroquinolones in rifampicin-resistant TB

    Article • The International Journal of Tuberculosis and Lung Disease, October 2021, International Union Against Tuberculosis and Lung Disease

    Dr Sabira Tahseen

  24. Estimation of country-specific tuberculosis antibiograms using genomic data

    Article • September 2021, openRxiv

    Dr Sabira Tahseen

  25. Design of Mannose-Coated Rifampicin nanoparticles modulating the immune response and Rifampicin induced hepatotoxicity with improved oral drug delivery

    Article • Arabian Journal of Chemistry, September 2021, Elsevier

    Dr Ibrahim Mohammad Ibrahim, Dr Sabira Tahseen

  26. Detection of active mycobacterium tuberculosis at 6th month exit among declared successfully treated cases in Pakistan

    Article • International Journal of Infectious Diseases, August 2021, Elsevier

    Dr Sabira Tahseen

  27. The role of epistasis in amikacin, kanamycin, bedaquiline, and clofazimine resistance in Mycobacterium tuberculosis complex

    Article • May 2021, openRxiv

    Dr Sabira Tahseen

  28. Mycobacterium tuberculosis borderline rpoB mutations: emerging from the unknown

    Article • European Respiratory Journal, April 2021, European Respiratory Society (ERS)

    Dr Sabira Tahseen

  29. Isolation of non-tuberculous mycobacteria among tuberculosis patients, a study from a tertiary care hospital in Lahore, Pakistan

    Article • BMC Infectious Diseases, April 2021, Springer Science + Business Media

    Dr Sabira Tahseen

  30. Investigating the intracellular bactericidal effects of rifampicin loaded S-protected thiomeric chitosan nanocargoes against Mycobacterium tuberculosis

    Article • Journal of Drug Delivery Science and Technology, February 2021, Elsevier

    Dr Sabira Tahseen

  31. Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan

    Article • International Journal of Mycobacteriology, January 2021, Medknow

    Dr Sabira Tahseen

  32. Second-line injectable drugs for rifampicin-resistant tuberculosis: better the devil we know?

    Article • Journal of Antimicrobial Chemotherapy, December 2020, Oxford University Press (OUP)

    Dr Sabira Tahseen

  33. Characterization of Genomic Variants Associated with Resistance to Bedaquiline and Delamanid in Naive Mycobacterium tuberculosis Clinical Strains

    Article • Journal of Clinical Microbiology, October 2020, ASM Journals

    Dr Sabira Tahseen

  34. 1653. Estimation of country-specific tuberculosis antibiograms using a wide and deep neural net on a large genomic dataset

    Article • Open Forum Infectious Diseases, October 2020, Oxford University Press (OUP)

    Dr Sabira Tahseen

  35. Population structure, biogeography and transmissibility of Mycobacterium tuberculosis

    Article • September 2020, openRxiv

    Dr Sabira Tahseen

  36. Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19

    Article • PLOS One, September 2020, PLOS

    Dr Sabira Tahseen

  37. Implementing universal rifampicin testing for TB in Pakistan: results and implications for the TB response

    Article • The International Journal of Tuberculosis and Lung Disease, August 2020, International Union Against Tuberculosis and Lung Disease

    Dr Sabira Tahseen

  38. Extrapulmonary tuberculosis in Pakistan- A nation-wide multicenter retrospective study

    Article • PLOS One, April 2020, PLOS

    Dr Sabira Tahseen

  39. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data

    Article • PLoS Medicine, January 2020, PLOS

    Dr Sabira Tahseen

  40. World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward

    Article • International Journal of Antimicrobial Agents, January 2020, Elsevier

    Dr Sabira Tahseen

  41. Antibiotic resistance prediction for Mycobacterium tuberculosis from genome sequence data with Mykrobe

    Article • Wellcome Open Research, December 2019, Faculty of 1000, Ltd.

    Dr Sabira Tahseen

  42. Acquisition of Cross-Resistance to Bedaquiline and Clofazimine following Treatment for Tuberculosis in Pakistan

    Article • Antimicrobial Agents and Chemotherapy, September 2019, ASM Journals

    Dr Sabira Tahseen

  43. In reply: A human rights-based approach to tuberculosis diagnosis

    Article • The International Journal of Tuberculosis and Lung Disease, August 2019, International Union Against Tuberculosis and Lung Disease

    Dr Sabira Tahseen

  44. Primary drug resistance in extra-pulmonary tuberculosis: a hospital-based prospective study from Pakistan

    Article • The International Journal of Tuberculosis and Lung Disease, August 2019, International Union Against Tuberculosis and Lung Disease

    Dr Sabira Tahseen

  45. DeepAMR for predicting co-occurrent resistance of Mycobacterium tuberculosis

    Article • Bioinformatics, January 2019, Oxford University Press (OUP)

    Dr Sabira Tahseen

  46. Is the public-private mix approach increasing tuberculosis case notification in Azad Jammu and Kashmir, Pakistan? A cross-sectional study

    Article • F1000Research, January 2019, Faculty of 1000, Ltd.

    Aashifa Yaqoob, Ahmad Wali, Razia Fatima, Dr Sabira Tahseen

  47. Sputum smear microscopy in the Xpert® MTB/RIF era

    Article • The International Journal of Tuberculosis and Lung Disease, January 2019, International Union Against Tuberculosis and Lung Disease

    Dr Sabira Tahseen

  48. Application of machine learning techniques to tuberculosis drug resistance analysis

    Article • Bioinformatics, November 2018, Oxford University Press (OUP)

    Dr Sabira Tahseen

  49. Prediction of Susceptibility to First-Line Tuberculosis Drugs by DNA Sequencing

    Article • The New England Journal of Medicine and Surgery and the Collateral Branches of Science, September 2018, New England Journal of Medicine (NEJM/MMS)

    Paolo Miotto, Jennifer Guthrie, Caroline Allix-Béguec, Dr Sabira Tahseen

  50. Validating a 14-Drug Microtiter Plate Containing Bedaquiline and Delamanid for Large-Scale Research Susceptibility Testing of Mycobacterium tuberculosis

    Article • Antimicrobial Agents and Chemotherapy, June 2018, ASM Journals

    Dr Daniela maria Cirillo, Dr Sabira Tahseen

  51. Reverse line probe assay for cheap detection of Single Nucleotide Polymorphisms in Mycobacterium tuberculosis

    Article • Tuberculosis, May 2018, Elsevier

    Dr Sabira Tahseen

  52. Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study

    Article • The Lancet Infectious Diseases, March 2018, Elsevier

    Paolo Miotto, Dr Sabira Tahseen

  53. Systematic case finding for tuberculosis in HIV-infected people who inject drugs: experience from Pakistan

    Article • The International Journal of Tuberculosis and Lung Disease, February 2018, International Union Against Tuberculosis and Lung Disease

    Dr Sabira Tahseen

  54. Evaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment

    Article • Clinical Microbiology and Infection, June 2017, Elsevier

    Paolo Miotto, Dr Sabira Tahseen

  55. Gastric specimens for diagnosing tuberculosis in adults unable to expectorate in Rawalpindi, Pakistan

    Article • Public Health Action, June 2017, International Union Against Tuberculosis and Lung Disease

    Dr Sabira Tahseen

  56. Fluoroquinolone consumption and -resistance trends in Mycobacterium tuberculosis and other respiratory pathogens: Ecological antibiotic pressure and consequences in Pakistan, 2009–2015

    Article • International Journal of Mycobacteriology, December 2016, Wolters Kluwer Health

    Dr Sabira Tahseen

  57. Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project

    Article • The Lancet Infectious Diseases, October 2016, Elsevier

    Dr Sabira Tahseen

  58. Read the new microscopy handbook: even the Ziehl-Neelsen technique has changed

    Article • The International Journal of Tuberculosis and Lung Disease, April 2016, International Union Against Tuberculosis and Lung Disease

    Dr Sabira Tahseen

  59. Use of Xpert® MTB/RIF assay in the first national anti-tuberculosis drug resistance survey in Pakistan

    Article • The International Journal of Tuberculosis and Lung Disease, April 2016, International Union Against Tuberculosis and Lung Disease

    Dr Sabira Tahseen

  60. Population Based National Tuberculosis Prevalence Survey among Adults (>15 Years) in Pakistan, 2010–2011

    Article • PLOS One, February 2016, PLOS

    Dr Sabira Tahseen

  61. EVALUATION OF DIAGNOSTIC POTENTIAL OF Rv3803c AND Rv2626c RECOMBINANT ANTIGENS IN TB ENDEMIC COUNTRY PAKISTAN

    Article • Journal of Immunoassay and Immunochemistry, December 2013, Taylor & Francis

    Dr Sabira Tahseen

  62. Xpert® MTB/RIF under routine conditions in diagnosing pulmonary tuberculosis: a study in two hospitals in Pakistan [Short communication]

    Article • Public Health Action, March 2013, International Union Against Tuberculosis and Lung Disease

    Dr Sabira Tahseen

  63. Plasma Antibody Profiles as Diagnostic Biomarkers for Tuberculosis

    Article • Clinical and Vaccine Immunology, October 2011, ASM Journals

    Dr Sabira Tahseen

  64. Delay in diagnosis of tuberculosis in Rawalpindi, Pakistan

    Article • BMC Research Notes, May 2011, Springer Science + Business Media

    Dr Sabira Tahseen

  65. Judging respiratory specimen acceptability for AFB microscopy: visual vs. microscopic screening

    Article • Tropical Medicine & International Health, May 2009, Wiley

    Dr Sabira Tahseen